PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project-Reference-Cited by-同舟云学术

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Published:2017-02 Issue:2 Volume:12 Page:208-222
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Hirsch Fred R.,McElhinny Abigail,Stanforth Dave,Ranger-Moore James,Jansson Malinka,Kulangara Karina,Richardson William,Towne Penny,Hanks Debra,Vennapusa Bharathi,Mistry Amita,Kalamegham Rasika,Averbuch Steve,Novotny James,Rubin Eric,Emancipator Kenneth,McCaffery Ian,Williams J. Andrew,Walker Jill,Longshore John,Tsao Ming Sound,Kerr Keith M.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A;Gettinger;J Clin Oncol,2015

2. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

5. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial;Rizvi;Lancet Oncol,2015

Cited by 1085 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

2. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

3. PTPRT loss enhances anti–PD-1 therapy efficacy by regulation of STING pathway in non–small cell lung cancer;Science Translational Medicine;2024-09-04

4. Letter to the editor: Comment on “the predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis”;Oral Oncology Reports;2024-09

5. Pulmonary Cytopathology;Surgical Pathology Clinics;2024-09